James Sandy
Corporate Officer/Principal chez F-STAR THERAPEUTICS, INC.
Profil
James Sandy is currently the Chief Development Officer at F-star Therapeutics, Inc. He previously worked as the Head of Development Operations at Pfizer Inc., Senior Vice President & Head of Development at Creabilis Therapeutics Srl and Creabilis Holdings Ltd., Head of Biometrics at Astra Pharmaceuticals Ltd., Chief Development Officer at Ellipses Pharma Ltd., and Chief Development Officer at Immunocore Holdings Plc.
He graduated from Imperial College London with a graduate degree and from the University of Brighton with an undergraduate degree.
Postes actifs de James Sandy
| Sociétés | Poste | Début |
|---|---|---|
| F-STAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2022 |
Anciens postes connus de James Sandy
| Sociétés | Poste | Fin |
|---|---|---|
Ellipses Pharma Ltd.
 Ellipses Pharma Ltd. Pharmaceuticals: MajorHealth Technology Ellipses Pharma Ltd. engages in the development of cancer medicines and treatment drugs. The company was founded by Christopher Evans and Rajan Jethwa in April 14, 2015 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
| IMMUNOCORE HOLDINGS PLC | Corporate Officer/Principal | - |
Astra Pharmaceuticals Ltd.
 Astra Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Astra Pharmaceuticals Ltd. manufactures & wholesales pharmaceutical products. The company was established in 1908 and is headquartered in London, GB | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Creabilis Holdings Ltd.
 Creabilis Holdings Ltd. Pharmaceuticals: MajorHealth Technology Creabilis Holdings Ltd. operates as a biotechnology company. The company was founded on June 7, 2013 and is headquartered in Canterbury, the United Kingdom. | Corporate Officer/Principal | - |
Formation de James Sandy
| Imperial College London | Graduate Degree |
| University of Brighton | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| Entreprise privées | 5 |
|---|---|
Creabilis Therapeutics Srl
 Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Health Technology |
Astra Pharmaceuticals Ltd.
Astra Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Astra Pharmaceuticals Ltd. manufactures & wholesales pharmaceutical products. The company was established in 1908 and is headquartered in London, GB | Health Technology |
Creabilis Holdings Ltd.
Creabilis Holdings Ltd. Pharmaceuticals: MajorHealth Technology Creabilis Holdings Ltd. operates as a biotechnology company. The company was founded on June 7, 2013 and is headquartered in Canterbury, the United Kingdom. | Health Technology |
Ellipses Pharma Ltd.
Ellipses Pharma Ltd. Pharmaceuticals: MajorHealth Technology Ellipses Pharma Ltd. engages in the development of cancer medicines and treatment drugs. The company was founded by Christopher Evans and Rajan Jethwa in April 14, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
